View Item 

Show simple item record

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
dc.contributor.authorMakrakis, Dimitrios
dc.contributor.authorTalukder, Rafee
dc.contributor.authorDiamantopoulos, Leonidas N.
dc.contributor.authorCarril-Ajuria, Lucia
dc.contributor.authorCastellano, Daniel
dc.contributor.authorDe Kouchkovsky, Ivan
dc.contributor.authorKoshkin, Vadim S.
dc.contributor.authorPark, Joseph J.
dc.contributor.authorAlva, Ajjai
dc.contributor.authorBilen, Mehmet A.
dc.contributor.authorStewart, Tyler F.
dc.contributor.authorMcKay, Rana R.
dc.contributor.authorSantos, Victor S.
dc.contributor.authorAgarwal, Neeraj
dc.contributor.authorJain, Jayanshu
dc.contributor.authorZakharia, Yousef
dc.contributor.authorMorales-Barrera, Rafael
dc.contributor.authorDevitt, Michael E.
dc.contributor.authorGrant, Michael
dc.contributor.authorLythgoe, Mark P.
dc.contributor.authorPinato, David J.
dc.contributor.authorNelson, Ariel
dc.contributor.authorHoimes, Christopher J.
dc.contributor.authorShreck, Evan
dc.contributor.authorGartrell, Benjamin A.
dc.contributor.authorSankin, Alex
dc.contributor.authorTripathi, Abhishek
dc.contributor.authorZakopoulou, Roubini
dc.contributor.authorBamias, Aristotelis
dc.contributor.authorMurgic, Jure
dc.contributor.authorFröbe, Ana
dc.contributor.authorRodriguez-Vida, Alejo
dc.contributor.authorDrakaki, Alexandra
dc.contributor.authorLiu, Sandy
dc.contributor.authorKumar, Vivek
dc.contributor.authorDi Lorenzo, Giuseppe
dc.contributor.authorJoshi, Monika
dc.contributor.authorIsaacsson-Velho, Pedro
dc.contributor.authorBuznego, Lucia Alonso
dc.contributor.authorDuran, Ignacio
dc.contributor.authorMoses, Marcus
dc.contributor.authorBarata, Pedro
dc.contributor.authorSonpavde, Guru
dc.contributor.authorYu, Evan Y.
dc.contributor.authorWright, Jonathan L.
dc.contributor.authorGrivas, Petros
dc.contributor.authorKhaki, Ali Raza
dc.date.accessioned2022-11-09T21:16:38Z
dc.date.available2023-12-09 16:16:36en
dc.date.available2022-11-09T21:16:38Z
dc.date.issued2022-11
dc.identifier.citationMakrakis, Dimitrios; Talukder, Rafee; Diamantopoulos, Leonidas N.; Carril-Ajuria, Lucia ; Castellano, Daniel; De Kouchkovsky, Ivan; Koshkin, Vadim S.; Park, Joseph J.; Alva, Ajjai; Bilen, Mehmet A.; Stewart, Tyler F.; McKay, Rana R.; Santos, Victor S.; Agarwal, Neeraj; Jain, Jayanshu; Zakharia, Yousef; Morales-Barrera, Rafael ; Devitt, Michael E.; Grant, Michael; Lythgoe, Mark P.; Pinato, David J.; Nelson, Ariel; Hoimes, Christopher J.; Shreck, Evan; Gartrell, Benjamin A.; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Murgic, Jure; Fröbe, Ana ; Rodriguez-Vida, Alejo ; Drakaki, Alexandra; Liu, Sandy; Kumar, Vivek; Di Lorenzo, Giuseppe; Joshi, Monika; Isaacsson-Velho, Pedro ; Buznego, Lucia Alonso; Duran, Ignacio; Moses, Marcus; Barata, Pedro; Sonpavde, Guru; Yu, Evan Y.; Wright, Jonathan L.; Grivas, Petros; Khaki, Ali Raza (2022). "Association of prior local therapy and outcomes with programmed- death ligand- 1 inhibitors in advanced urothelial cancer." BJU International (5): 592-603.
dc.identifier.issn1464-4096
dc.identifier.issn1464-410X
dc.identifier.urihttps://hdl.handle.net/2027.42/175056
dc.publisherWiley Periodicals, Inc.
dc.subject.other#BladderCancer
dc.subject.otherbladder cancer
dc.subject.otherurinary tract neoplasms
dc.subject.otherurothelial carcinoma
dc.subject.otherimmune checkpoint inhibitors
dc.subject.otherimmunotherapy
dc.subject.otheroutcomes
dc.subject.other#uroonc
dc.subject.other#utuc
dc.subject.other#blcsm
dc.titleAssociation of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175056/1/bju15603_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175056/2/bju15603-sup-0003-TableS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175056/3/bju15603-sup-0002-FigS2.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175056/4/bju15603.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175056/5/bju15603-sup-0001-FigS1.pdf
dc.identifier.doi10.1111/bju.15603
dc.identifier.sourceBJU International
dc.identifier.citedreferenceBajorin DF, Witjes JA, Gschwend J, Schenker M. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 2021; 39 ( 6_suppl ): 391
dc.identifier.citedreferenceAbufaraj M, Gust K, Moschini M et al. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Transl Androl Urol 2016; 5: 735 – 44
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7 – 30
dc.identifier.citedreferenceHussain MHA, Powles T, Albers P et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 2020; 38 ( 15_suppl ): 5000
dc.identifier.citedreferencevan Dijk N, Gil-Jimenez A, Silina K et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 2020; 26: 1839 – 44
dc.identifier.citedreferencePowles T, Kockx M, Rodriguez-Vida A et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25: 1706 – 14
dc.identifier.citedreferenceNecchi A, Anichini A, Raggi D et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2018; 36: 3353 – 60
dc.identifier.citedreferenceHorowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 2015; 12: 213 – 26
dc.identifier.citedreferenceGrivas P, Plimack ER, Balar AV et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): Outcomes in older patients by age and performance status. Eur Urol Oncol 2020; 3: 351 – 9
dc.identifier.citedreferenceSundahl N, Vandekerkhove G, Decaestecker K et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol 2019; 75: 707 – 11
dc.identifier.citedreferenceDaro-Faye M, Kassouf W, Souhami L et al. Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World J Urol 2021; 39: 1331 – 43
dc.identifier.citedreferenceRompré-Brodeur A, Shinde-Jadhav S, Ayoub M et al. PD-1/PD-L1 Immune checkpoint inhibition with radiation in bladder cancer. In Situ and Abscopal Effects. Mol Cancer Ther 2020; 19: 211 – 20
dc.identifier.citedreferenceMoschini M, Xylinas E, Zamboni S et al. Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter. Multidisciplinary Database. Eur Urol Oncol 2020; 3: 94 – 101
dc.identifier.citedreferenceAbufaraj M, Dalbagni G, Daneshmand S et al. The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol 2018; 73: 543 – 57
dc.identifier.citedreferenceLi R, Metcalfe M, Kukreja J, Navai N. Role of radical cystectomy in non-organ confined bladder cancer: a systematic review. Bladder Cancer 2018; 4: 31 – 40
dc.identifier.citedreferenceAmin S, Baine MJ, Meza JL, Lin C. Association of immunotherapy with survival among patients with brain metastases whose cancer was managed with definitive surgery of the primary tumor. JAMA Netw Open 2020; 3: e2015444
dc.identifier.citedreferenceBellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850 – 5
dc.identifier.citedreferenceHarris PA, Taylor R, Thielke R et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377 – 81
dc.identifier.citedreferenceHarris PA, Taylor R, Minor BL et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95: 103208
dc.identifier.citedreferenceKhaki AR, Li A, Diamantopoulos LN et al. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer 2020; 126: 1208 – 16
dc.identifier.citedreferenceEsagian SM, Khaki AR, Diamantopoulos LN et al. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 2021; 128: 196 – 205
dc.identifier.citedreferenceKhaki AR, Li A, Diamantopoulos LN et al. A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors [published online ahead of print, 2021 Jan 7]. Eur Urol Oncol 2021; 4: 464 – 72
dc.identifier.citedreferenceMiller NJ, Khaki AR, Diamantopoulos LN et al. Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study. J Urol 2020; 204: 63 – 70
dc.identifier.citedreferenceSingla N, Hutchinson RC, Ghandour RA et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol 2020; 38: 604.e9 – 604.e17
dc.identifier.citedreferenceGopalakrishnan D, Koshkin VS, Ornstein MC et al. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag 2018; 14: 1019 – 40
dc.identifier.citedreferencePowles T, Durán I, van der Heijden MS et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748 – 57
dc.identifier.citedreferencePowles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383: 1218 – 30
dc.identifier.citedreferenceSargos P, Baumann BC, Eapen L et al. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev 2018; 70: 88 – 97
dc.identifier.citedreferenceMari A, Campi R, Tellini R et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World J Urol 2018; 36: 157 – 70
dc.identifier.citedreferenceMoschini M, Zamboni S, Karnes JR et al. Clinical recurrence after radical cystectomy for bladder cancer, defining optimal surveillance after surgery. Eur Urol Supp 2019; 18: e1144
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bju15603_am.pdf
Size:
881.6KB
Format:
PDF
View/Open
Name:
bju15603-sup-0003-TableS1.pdf
Size:
36.11KB
Format:
PDF
View/Open
Name:
bju15603-sup-0002-FigS2.pdf
Size:
554.1KB
Format:
PDF
View/Open
Name:
bju15603.pdf
Size:
437.3KB
Format:
PDF
View/Open
Name:
bju15603-sup-0001-FigS1.pdf
Size:
550.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.